Objective To investigate the serum expressions of vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1) and C1q/tumor necrosis factor-related protein 3 (CTRP3) in type II diabetic rats with atheroscle?rosis and to undermine the interventional mechanism of simvastatin. Methods SD rats were randomly divided into normal diet (NC) group (n=8), high-fat diet (HFD) group (n=8), high-fat diet intervention (HFD+S) group (n=8), model (M) group (n=18) and model intervention (M+S) group (n=16). The diabetic atherosclerosis model was established by streptozotocin (STZ)+Vitamin D3(VitD3)+High-fat diet. The group HFD+S and group M+S rats were administrated with simvastatin at 20 mg/(kg·d)intragastrically as intervention while distilled water [20 mL/(kg·d)] were given to other groups. Serum levels of fasting plasma glucose(FPG), blood lipid, fasting insulin(FINS), VEGF, TGF-β1 and CTRP3 were compared between each groups. Results Characteristics of atheromatous plaque were seen in group M and group M+S whose pathological change were markedly attenuated compared to group M. Serum levels of VEGF, TGF-β1 and CTRP3 were significantly high?er in rats from Group HFD than those in rats from group NC. Serum levels of VEGF and TGF-β1 were significantly higher in rats from Group M than those in rats from group NC. Serum level of VEGF was significantly higher in rats from Group M than it in rats from group HFD. Serum level of CTRP3 was significantly lower in rats from Group M than it in rats from group HFD. Moreover, serum levels of TGF-β1 and CTRP3 were significantly higher in rats from Group HFD+S than those in rats from group HFD after the intervention with simvastatin. Serum level of VEGF was significantly lower in rats from Group M+S than it in rats from group M, and serum levels of TGF-β1 and CTRP3 were significantly higher in rats from group M+S than those in rats from group M after the intervention with simvastatin. Conclusion VEGF, TGF-β1 and CTRP3 may partici?pate in development of diabetic atherosclerosis. In addition to its hypolipidemic role, Simvastatin can also down regulate se?rum level of VEGF and up regulate serum levels of TGF-β1 and CTRP3 to exert a significant protective effect on diabetic atherosclerosis.

Objective To investigate the role of GABAAα3and GABAB receptors in the ventrolateral periaqueductal gray in the development of paw acute pain in rats.Methods Twelve male SD rats, weighing 280~320 g, were randomly divided into two groups: normal saline group (group NS), formaldehyde-induced pain group (group F), 6 rats in each group.In group F, rats were subcutaneously injected with 2% formaldehyde 50 μl into the ventral surface of right hind paw to induce periphery inflammatory pain.In group NS, rats were subcutaneously injected with normal saline into the ventral surface of right hind paw.Mechanical threshold was assessed using von Frey hairs for every ten minutes.The rat pain behavior scores were recorded for every five minutes.The thickness of skin and skin temperature were recorded for every fifteen minutes.Results Mechanical hyperalgesia were induced in group F after formalin injection into right hind paw.Compared with group NS, rat pain behavior scores were increased significantly in group F at all time points after injection, mechanical threshold were decreased significantly in group F at 10-60 min after injection, the temperature of the skin and the skin thickness were increased significantly in group F at 15-60 min after injection (P<0.05), the levels of the expression of GABAAα3 and GABAB were significantly increased in group F (P<0.05).Conclusion GABAAα3and GABAB receptors mediates formalin-induced hyperalgesia at ventrolateral portion of the PAG (vlPAG) of rats.

Objective This study was designed to investigate influence of resveratrol on serum lipid and antioxidant enzyme lev‐els in atherosclerotic rabbit model ,and to explore its influence on NF‐κB and MAPKs signal pathway .Methods Rabbits were as‐signed to five groups :control (group A) ,high fat diet group (group B) ,resveratrol group (group C ,D and E) .The contents of lip‐ids level (TC ,TG ,LDL‐C ,HDL‐C) and antioxidant enzyme (GSH ,GSH‐PX ,GST ,γ‐GCS ,CAT ,SOD ,MDA) levels in the serum were measured respectively and the difference was studied .Phosphorylation levels of MAPKs cascades ,NF‐κB were measured by Western blot .Results Compared with group A ,group B had elevated levels of blood lipids ,antioxidant enzymes were on the de‐cline ,the MDA content increased ,MAPKs and the NF‐κB protein phosphorylation enhanced .C ,D ,E group can reduce levels of blood lipids ,increases HDL‐C ,improve antioxidant enzyme activity and reduce MDA content ,inhibit MAPKs ,NF‐κB protein phos‐phorylation .Conclusion Resveratrol could reduce the atherosclerotic rabbit blood lipid levels ,increase antioxidant enzyme activity , reduce the MDA level and this effect is likely to inhibit NF‐κB and MAPKs signaling pathway activation .

Objective:To investigate the effect of repetitive transcranial magnetic stimulation combined with cognitive function training on improving cognitive and psychological and behavioral symptoms in patients with vascular dementia.Methods:A total of 80 patients with vascular dementia who received treatment at The Third People's Hospital of Huzhou from October 2020 to October 2022 were included in this study. They were divided into a control group and an observation group ( n = 40 per group) based on different treatment methods. The control group received repetitive transcranial magnetic stimulation, while the observation group received both repetitive transcranial magnetic stimulation and cognitive function training. Both groups were treated continuously for 4 weeks. The scores of The Mini-Mental State Examination (MMSE), the Behavioral Pathology in Alzheimer's Disease Rating Scale (BE-HAVE-AD), Activities of Daily Living (ADL), and Pittsburgh Sleep Quality Index (PSQI) of the two groups were analyzed before and after treatment. Additionally, serum levels of homocysteine and neuron-specific enolase in both groups were compared before and after treatment. The clinical efficacy of the two groups was evaluated, and the total response rate was calculated. Adverse reactions occurring during the treatment period in both groups were also recorded. Results:Before treatment, the Mini-Mental State Examination (MMSE) scores for the control and observation groups were (14.92 ± 2.43) points and (14.83 ± 2.56) points, respectively. After treatment, the scores were (22.81 ± 3.05) points for the control group and (25.62 ± 4.07) points for the observation group. After treatment, the MMSE scores in both groups were significantly higher than the respective levels before treatment in the corresponding group, and the observation group had a significantly higher score than the control group ( t = 2.25, P < 0.05). Before treatment, the BE-HAVE-AD scores for the control and observation groups were (45.28 ± 6.27) points and (44.95 ± 6.38) points, respectively. After treatment, the scores were (27.54 ± 2.22) points for the control group and (23.07 ± 1.79) points for the observation group. After treatment, the BE-HAVE-AD scores were significantly lower than those before treatment in each group, and the observation group had a significantly lower score than the control group ( t = 9.56, P < 0.05). Before treatment, the ADL scores for the control and observation groups were (23.17 ± 1.43) points and (22.83 ± 1.64) points, respectively. After treatment, the scores were (38.27 ± 3.25) points for the control group and (41.52 ± 4.26) points for the observation group. After treatment, the ADL scores in each group were significantly higher than their respective levels before treatment, and the observation group had a significantly higher score than the control group ( t = 3.83, P < 0.05). Before treatment, the PSQI scores for the control and observation groups were (16.423 ± 1.51) points and (15.86 ± 1.49) points, respectively. After treatment, the scores were (9.16 ± 1.12) points for the control group and (7.07 ± 1.07) points for the observation group. After treatment, the PSQI scores were significantly lower than those before treatment in each group, and the observation group had a significantly lower score than the control group ( t = 8.53, P < 0.05). Before treatment, the serum levels of homocysteine in the control and observation groups were (54.27 ± 8.21) ng/L and (55.13 ± 7.64) ng/L, respectively, while the serum levels of neuron-specific enolase in these two groups were (59.66 ± 9.51) μg/L and (60.97 ± 10.29) μg/L, respectively. After treatment, the serum levels of homocysteine in the control and observation groups were (30.63 ± 1.95) ng/L and (25.57 ± 2.06) ng/L, respectively, and the serum levels of neuron-specific enolase in these two groups were (49.23 ± 6.12) μg/L and (37.21 ± 7.01) μg/L, respectively. After treatment, the serum levels of homocysteine and neuron-specific enolase in each group were significantly lower than the respective levels before treatment in the corresponding group; the observation group exhibited significantly lower serum levels of homocysteine and neuron-specific enolase than the control group ( t = 11.28, 8.16, both P < 0.05). The total response rate in the observation group was 95.00% (38/40), which was significantly higher than that in the control group [72.50% (29/40), P < 0.05]. The incidence of adverse reactions in the observation group was 5.00% (2/40), which was significantly lower than that in the control group [20.00% (8/40), χ2 = 7.44, P < 0.05]. Conclusion:Repetitive transcranial magnetic stimulation combined with cognitive function training can more effectively improve cognitive and psychological and behavioral symptoms in patients with vascular dementia, has better efficacy, and is safer compared with repetitive transcranial magnetic stimulation alone.